5-Hour Energy: A Success Equal Parts Caffeine, Chemistry and…
Suddenly, Amazon Doesn't Love Its Moms Anymore
Look for Sequenom, Inc. (NASDAQ: SQNM) to be smacked hard by selling pressure today. Late Wednesday, the company reported that improper handling of research and development test data and results by its employees has delayed the launch of its Down's Syndrome test. Sequenom said it's forming a special committee to investigate employee activity related to the tainted test data.
The company's SEQureDx tests the DNA of a fetus, via the mother's blood, in order to determine whether their blood groups are compatible. Although Sequenom can no longer rely on previously announced test data and results, Chief Executive Harry Stylli asserted, "We are not back at square one" on a conference call.
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
